Journal of geriatric oncology最新文献

{"title":"Potential drug-drug interactions between cancer therapies and active antiretroviral treatments among Medicare-enrolled patients with cancer and HIV","authors":"Jessica Y. Islam , Xi Zhou , Christopher Baggett , Christine Jamjian , Anna Coghill , Gita Suneja , Jennifer L. Lund","doi":"10.1016/j.jgo.2024.102158","DOIUrl":"10.1016/j.jgo.2024.102158","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102158"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Start low, go slow,” a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis","authors":"Gabriel Aleixo , Tej Patel , Julianne Ani , Will J. Ferrell , Efrat Dotan , Samuel U. Takvorian , Grant R. Williams , Ravi B. Parikh , Ramy Sedhom","doi":"10.1016/j.jgo.2024.102153","DOIUrl":"10.1016/j.jgo.2024.102153","url":null,"abstract":"<div><h3>Introduction</h3><div>The use of standard-dose cancer treatment can result in a decline in the functional abilities of older adults with cancer. The “start-low, go-slow” (SLGS) strategy involves initiating cancer treatment at lower-than-standard doses in selected patients who are vulnerable to excess toxicity and escalating based on tolerance. We performed a systematic review and meta-analysis to assess the available data and the effectiveness of the SLGS strategy in the treatment of cancer in older adults with incurable solid cancer.</div></div><div><h3>Materials and Methods</h3><div>The review was registered with PROSPERO. Two independent reviewers (GA and TP) conducted a comprehensive search across multiple databases (PubMed/Medline, Journal of Geriatric Oncology, American Society of Clinical Oncology abstracts, and EMBASE) of prospective studies involving patients with solid tumors who received SLGS. SLGS was defined as starting cancer therapy with a lower than standard dose and dose-escalating, if possible. The main objective of this study was to evaluate overall survival (OS) in patients treated with the SLGS strategy. Secondary objectives were to analyze treatment discontinuation and toxicity in patients treated with the SLGS strategy. Additionally, we aimed to compile a comprehensive report on studies employing the SLGS strategy in solid oncology. We utilized a random-effects meta-analysis model to consider the diversity among patient populations with different cancer stages, types, and treatments. Two researchers independently employed the Newcastle-Ottawa Quality (NOQ) assessment for cohort analysis to evaluate the methodological quality and standard of outcomes reporting in the included studies. The quality of evidence was appraised using the Grading recommendations assessment, development and evaluation GRADE summary of findings tool.</div></div><div><h3>Results</h3><div>The systematic search identified a total of 12,690 articles. Thirteen studies met criteria for inclusion in the systematic review, totaling 8546 patients. Twelve studies evaluated OS. However, only five studies focused solely on older adults, and the studies involved different types of cancer without following a specific pattern. In meta-analysis of survival among three studies, patients who underwent the SLGS approach had lower mortality (hazar ratio 0.91, 95 % confidence interval [CI] 0.85–0.98, <em>p</em> = 0.01, i2 = 0 %). Toxicity ranged from 5 % to 89 % across studies; SLGS had lower grade 3 and 4 toxicity compared to the standard dose (six studies, meta-analysis relative risk 0.86, 95 % CI 0.75–0.98, <em>p</em> < 0.02, i2 = 30 %). Treatment discontinuation was not different for SLGS vs. standard dose (seven studies, meta-analysis RR 0.96, 95 % CI 0.87–1.05, <em>p</em> = 0.37 i2 = 50 %).</div></div><div><h3>Discussion</h3><div>This systematic review and meta-analysis suggests that a SLGS approach to systemic therapy dosing may reduce toxicity without","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102153"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3","authors":"Kah Poh Loh ,&nbsp;Qiao Ming Rachel Ng ,&nbsp;Supriya G. Mohile ,&nbsp;Sally Norton ,&nbsp;Ronald M. Epstein ,&nbsp;Michael B. Sohn ,&nbsp;Daniel Richardson ,&nbsp;Omer Jamy ,&nbsp;Soroush Mortaz Hedjri ,&nbsp;Rachel Blumberg ,&nbsp;Laura Nafis ,&nbsp;Marielle Jensen-Battaglia ,&nbsp;Ying Wang ,&nbsp;Jason Mendler ,&nbsp;Jane Liesveld ,&nbsp;Eric J. Huselton ,&nbsp;Rachel Rodenbach ,&nbsp;Jozal Moore ,&nbsp;Craig Maguire ,&nbsp;Steve M. Buechler ,&nbsp;Heidi D. Klepin","doi":"10.1016/j.jgo.2025.102187","DOIUrl":"10.1016/j.jgo.2025.102187","url":null,"abstract":"<div><h3>Introduction</h3><div>Therapeutic advances have allowed more adults aged ≥60 years with acute myeloid leukemia (AML) to receive life-prolonging treatments, with improvement in overall survival. In contrast to other cancers, the onset of AML is often sudden, high-risk treatment decisions must be made quickly, and survival is often compromised due to aging-related conditions (e.g., functional impairments). Studies have demonstrated that up to 78 % of older adults with AML and their caregivers experience significant psychological distress. Distress is associated with poor quality of life, increased healthcare utilization, and increased mortality. Shared decision making (SDM) can reduce patient and caregiver distress and is essential to achieve goal-concordant care. Therefore, interventions to alleviate distress and optimize SDM in older adults with AML and their caregivers are needed. We will conduct a multicenter randomized controlled trial to evaluate the efficacy of <u>U</u>niversity of <u>R</u>ochester-<u>G</u>eriatric <u>O</u>ncology assessment for <u>A</u>cute myeloid <u>L</u>eukemia (UR-GOAL) compared to an attention control for reducing patient distress and improving observed SDM, patient-perceived SDM, and decisional conflict.</div></div><div><h3>Material and Methods</h3><div>We will recruit 300 patients aged ≥60 years with newly diagnosed AML, their caregivers (one caregiver per patient when available), and up to 40 oncologists from four institutions: (1) Patients will view an educational video about AML diagnosis, treatment, and prognosis; complete the Best Worst Scaling values clarification process; and review a summary report of their values with tailored question prompts and resources; (2) Caregivers will view the same educational video and receive the same summary report as patients; and (3) Oncologists will review a summary report of the patient's aging-related conditions, perception of prognosis, and values. Patients, caregivers, and oncologists will then meet during clinical visits to discuss aging-related conditions, prognosis, and patient values, and reach a treatment decision. The primary outcome measure is distress (Distress Thermometer). Secondary outcome measures include observed SDM, patient perceived SDM, and decisional conflict.</div></div><div><h3>Discussion</h3><div>This study will address significant knowledge gaps related to reducing distress and decisional conflict and improving SDM in older adults with AML. If successful, this research will inform future decisional interventions for a broader group of patients.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102187"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smartphone application for longitudinal home gait speed measurement in older adults with blood cancers: A feasibility and acceptability study","authors":"Pei-An Lee ,&nbsp;Clark DuMontier ,&nbsp;Nicholas Groblewski ,&nbsp;Wanting Yu ,&nbsp;Junhong Zhou ,&nbsp;Tammy Hshieh ,&nbsp;Dae Kim ,&nbsp;Tom Travison ,&nbsp;Jane Driver ,&nbsp;On-Yee Lo ,&nbsp;Brad Manor ,&nbsp;Gregory Abel","doi":"10.1016/j.jgo.2024.102132","DOIUrl":"10.1016/j.jgo.2024.102132","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102132"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic and procedural challenges in transitioning patients with cancer to post-acute and long-term care facilities: A prospective mixed-methods study","authors":"Oisharya Dasgupta ,&nbsp;Nabiel Mir ,&nbsp;Kunal Desai ,&nbsp;Lauren J. Gleason","doi":"10.1016/j.jgo.2024.102154","DOIUrl":"10.1016/j.jgo.2024.102154","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102154"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing observational studies to estimate treatment effects in geriatric oncology: A closer look at confounding and its mitigation","authors":"Nienke A. de Glas ,&nbsp;Sophie Pilleron ,&nbsp;Esther Bastiaannet ,&nbsp;Florence Canouï-Poitrine ,&nbsp;Adolfo González Serrano ,&nbsp;Eva Culakova ,&nbsp;Jennifer L. Lund","doi":"10.1016/j.jgo.2024.102159","DOIUrl":"10.1016/j.jgo.2024.102159","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102159"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The International Society of Geriatric Oncology (SIOG) Methods Working Group","authors":"Sophie Pilleron ,&nbsp;Esther Bastiaannet ,&nbsp;Carine Bellera ,&nbsp;Florence Canouï-Poitrine ,&nbsp;Eva Culakova ,&nbsp;Nienke de Glas ,&nbsp;Adolfo González Serrano ,&nbsp;Kristen R. Haase ,&nbsp;Jessica L. Krok-Schoen ,&nbsp;Tomonori Mizutani ,&nbsp;India Pinker ,&nbsp;Jennifer Lund","doi":"10.1016/j.jgo.2025.102217","DOIUrl":"10.1016/j.jgo.2025.102217","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102217"},"PeriodicalIF":3.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal associations between symptom burden and fall risks in older adults with a cancer history: Findings from the 2011–2015 National Health and Aging Trends Study","authors":"Myeongjin Bae ,&nbsp;Nancy M. Gell","doi":"10.1016/j.jgo.2025.102212","DOIUrl":"10.1016/j.jgo.2025.102212","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102212"},"PeriodicalIF":3.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan","authors":"Yuki Kobari ,&nbsp;Junpei Iizuka ,&nbsp;Hanae Kondo ,&nbsp;Makiko Ichioka ,&nbsp;Shun Watanabe ,&nbsp;Kazutaka Nakamura ,&nbsp;Toshihide Horiuchi ,&nbsp;Shinsuke Mizoguchi ,&nbsp;Kazuhiko Yoshida ,&nbsp;Hiroaki Shimmura ,&nbsp;Yasunobu Hashimoto ,&nbsp;Tsunenori Kondo ,&nbsp;Hiroshi Kobayashi ,&nbsp;Toshio Takagi","doi":"10.1016/j.jgo.2025.102216","DOIUrl":"10.1016/j.jgo.2025.102216","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102216"},"PeriodicalIF":3.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143463857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: A systematic review","authors":"Aaron Sia ,&nbsp;Sakshi Chopra ,&nbsp;Victoria Y. Ling ,&nbsp;James Fletcher ,&nbsp;Ruth Eleanor Hubbard ,&nbsp;Peter Mollee ,&nbsp;Emily Gordon ,&nbsp;Natasha Reid ,&nbsp;Leila Shafiee Hanjani","doi":"10.1016/j.jgo.2025.102196","DOIUrl":"10.1016/j.jgo.2025.102196","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute myeloid leukaemia (AML) is a disease of the older person. Due to the demands of intensive chemotherapy, there is a significant risk of over or undertreatment, leading to either iatrogenic harm or missed windows of opportunity for remission or cure. Better tools to aid clinical decision making and risk stratify patients are needed. We aimed to investigate the association between frailty and the treatment and disease-related outcomes of adults receiving systemic therapy for AML.</div></div><div><h3>Materials and Methods</h3><div>A systematic search of PubMed, EMBASE, CINAHL, and Web of Science databases was undertaken for studies assessing frailty (defined as multi-dimensional assessment evaluating two or more geriatric relevant domains or usage of a validated geriatric assessment screening tool) in the setting of adults undergoing systemic therapy for AML.</div></div><div><h3>Results</h3><div>We identified 6,644 publications, 16 of which met inclusion criteria for extraction. The most commonly described outcomes were overall survival (OS) (<em>n</em> = 12), mortality (<em>n</em> = 8), response rate (<em>n</em> = 6), and high grade toxicity (<em>n</em> = 5). Eleven studies correlated frailty with treatment outcomes: frailty was predictive of lower OS (n = 5), higher mortality (<em>n</em> = 3), and more high grade toxicity (<em>n</em> = 1). OS in particular retained this relationship when controlling for variables such as molecular markers and performance status. Significant heterogeneity in outcome reporting and frailty assessment precluded meta-analysis. Included studies were generally of moderate quality.</div></div><div><h3>Discussion</h3><div>Frailty was predictive of poorer outcomes in patients with AML distinct from and complimentary to traditional disease prognostic schema. Routine implementation of frailty assessment could represent an important tool to risk stratify patients and improve clinical decision making.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102196"},"PeriodicalIF":3.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143454884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}